NVR 3-778, a first-in-class HBV core inhibitor, alone and in combination with peg-interferon (PEGIFN), in treatment-naïve HBeAg-positive patients: early reductions in HBV DNA and HBsAg
Refereed conference paper presented and published in conference proceedings


Full Text

Other information
All Author(s) ListYUEN Mf, KIM Dj, WEILERT F, CHAN Lik Yuen Henry, LALEZARI Jp, HWANG Sg, NGUYEN T, LIAW S, BROWN N, KLUMPP K, FLORES O, HARTMAN G, GANE E
Name of ConferenceAnnual Meeting of the European Association for the Study of the Liver
Proceedings TitleAnnual Meeting of the European Association for the Study of the Liver
Detailed descriptionorganized by EASL,
Year2016
Month4
Pages2
LanguagesEnglish-United Kingdom

Last updated on 2018-19-01 at 02:30